Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (411-420 of 609) with videos related to

Pageof 61
Sort By:
The Journal of Experimental Medicine|December 1, 1995
Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cellsJ G Krueger, J T Wolfe, R T Nabeya, et al.
Plos One|April 12, 2012
Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasisYumiko Wada, Irma Cardinale, Artemis Khatcherian, et al.
Dermatology and Therapy|March 13, 2022
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBoni E Elewski, Andrew Blauvelt, Gaia Gallo, et al.
Journal of the American Academy of Dermatology|June 1, 2020
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension studyAndrew Blauvelt, Kim A Papp, Joseph F Merola, et al.
The Journal of Rheumatology|July 15, 2024
Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual MeetingGretchen D Ball, Danielle Yee, Arianna J Zhang, et al.
Journal of the American Academy of Dermatology|October 26, 2002
Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibodyAlice B Gottlieb, Mark Lebwohl, Mark C Totoritis, et al.
Journal of Clinical Pharmacology|February 11, 2005
Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasisDeborah L Mortensen, Patricia A Walicke, Xiaolin Wang, et al.
The Journal of Dermatological Treatment|September 14, 2007
Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) studyAlice B Gottlieb, Leon Kircik, Drore Eisen, et al.
Journal of the American Academy of Dermatology|January 15, 2017
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanerceptBruce Strober, Alice B Gottlieb, Bintu Sherif, et al.
The British Journal of Dermatology|March 8, 2022
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritisKristian Reich, Xenophon Baraliakos, Laura C Coates, et al.
Pageof 61

Showing results (411-420 of 609) with videos related to

Sort By:
Pageof 61
The Journal of Experimental Medicine|December 1, 1995
Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cellsJ G Krueger, J T Wolfe, R T Nabeya, et al.
Plos One|April 12, 2012
Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasisYumiko Wada, Irma Cardinale, Artemis Khatcherian, et al.
Dermatology and Therapy|March 13, 2022
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBoni E Elewski, Andrew Blauvelt, Gaia Gallo, et al.
Journal of the American Academy of Dermatology|June 1, 2020
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension studyAndrew Blauvelt, Kim A Papp, Joseph F Merola, et al.
The Journal of Rheumatology|July 15, 2024
Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual MeetingGretchen D Ball, Danielle Yee, Arianna J Zhang, et al.
Journal of the American Academy of Dermatology|October 26, 2002
Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibodyAlice B Gottlieb, Mark Lebwohl, Mark C Totoritis, et al.
Journal of Clinical Pharmacology|February 11, 2005
Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasisDeborah L Mortensen, Patricia A Walicke, Xiaolin Wang, et al.
The Journal of Dermatological Treatment|September 14, 2007
Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) studyAlice B Gottlieb, Leon Kircik, Drore Eisen, et al.
Journal of the American Academy of Dermatology|January 15, 2017
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanerceptBruce Strober, Alice B Gottlieb, Bintu Sherif, et al.
The British Journal of Dermatology|March 8, 2022
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritisKristian Reich, Xenophon Baraliakos, Laura C Coates, et al.
Pageof 61